WO2002012336A3 - TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE - Google Patents

TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE Download PDF

Info

Publication number
WO2002012336A3
WO2002012336A3 PCT/US2001/004192 US0104192W WO0212336A3 WO 2002012336 A3 WO2002012336 A3 WO 2002012336A3 US 0104192 W US0104192 W US 0104192W WO 0212336 A3 WO0212336 A3 WO 0212336A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutics
methods
proteins
compositions
tgf
Prior art date
Application number
PCT/US2001/004192
Other languages
French (fr)
Other versions
WO2002012336A2 (en
WO2002012336A9 (en
Inventor
Monica Wang
Kevin Pang
Original Assignee
Curis Inc
Monica Wang
Kevin Pang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc, Monica Wang, Kevin Pang filed Critical Curis Inc
Priority to AU2001238091A priority Critical patent/AU2001238091A1/en
Publication of WO2002012336A2 publication Critical patent/WO2002012336A2/en
Publication of WO2002012336A9 publication Critical patent/WO2002012336A9/en
Publication of WO2002012336A3 publication Critical patent/WO2002012336A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]

Abstract

The present invention relates to TGFβ therapeutics, TGFβ proteins or a combination of TGFβ proteins which are capable of stimulating growth and/or differentiation of pancreatic tissue. The invention also relates to pharmaceutical compositions comprising such proteins and/or therapeutics, methods for using such proteins and/or therapeutics in culturing pancreatic tissue and cells and methods for administering such proteins and/or therapeutics to a subject.
PCT/US2001/004192 2000-08-09 2001-02-09 TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE WO2002012336A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001238091A AU2001238091A1 (en) 2000-08-09 2001-02-09 Tgf-beta therapeutics, compositions and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63536800A 2000-08-09 2000-08-09
US09/635,368 2000-08-09

Publications (3)

Publication Number Publication Date
WO2002012336A2 WO2002012336A2 (en) 2002-02-14
WO2002012336A9 WO2002012336A9 (en) 2002-10-10
WO2002012336A3 true WO2002012336A3 (en) 2003-08-14

Family

ID=24547507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004192 WO2002012336A2 (en) 2000-08-09 2001-02-09 TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE

Country Status (2)

Country Link
AU (1) AU2001238091A1 (en)
WO (1) WO2002012336A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612040B2 (en) 2005-07-01 2009-11-03 Acceleron Pharma Inc. Lefty polypeptides and derivatives thereof
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
GB0604964D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Protein folding
GB0604966D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542679A1 (en) * 1991-11-11 1993-05-19 Ciba-Geigy Ag Novel hybrid transforming growth factors
US5409896A (en) * 1989-09-01 1995-04-25 Genentech, Inc. TGF-β composition for inducing bone growth
US5656587A (en) * 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
WO2000047243A2 (en) * 1999-02-10 2000-08-17 Ontogeny, Inc. Pancreatic ductal trophic factors, uses and composition related thereto
WO2001039784A1 (en) * 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656587A (en) * 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US5409896A (en) * 1989-09-01 1995-04-25 Genentech, Inc. TGF-β composition for inducing bone growth
US5604204A (en) * 1989-09-01 1997-02-18 Genentech, Inc. Method of inducing bone growth using TGF-β
EP0542679A1 (en) * 1991-11-11 1993-05-19 Ciba-Geigy Ag Novel hybrid transforming growth factors
WO2000047243A2 (en) * 1999-02-10 2000-08-17 Ontogeny, Inc. Pancreatic ductal trophic factors, uses and composition related thereto
WO2001039784A1 (en) * 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALVAREZ A ET AL: "Regulation of pancreatic duct cell growth by transforming growth factor beta (TGFbeta) in vitro", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 114, no. 4 PART 2, 15 April 1998 (1998-04-15), pages A1375, XP000925857, ISSN: 0016-5085 *
MIRALLES FRANCISCO ET AL: "TGF-beta plays a key role in morphogenesis of the pancreatic islets of Langerhans by controlling the activity of the matrix metalloproteinase MMP-2", JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, NEW YORK, US, US, vol. 143, no. 3, 2 November 1998 (1998-11-02), pages 827 - 836, XP002148144, ISSN: 0021-9525 *
SANVITO F ET AL: "TGF-beta-1 influences the relative development of the exocrine and endocrine pancreas in vitro", DEVELOPMENT, COMPANY OF BIOLOGISTS, CAMBRIDGE,, GB, vol. 120, no. 12, 1994, pages 3451 - 3462, XP002148143, ISSN: 0950-1991 *

Also Published As

Publication number Publication date
WO2002012336A2 (en) 2002-02-14
AU2001238091A1 (en) 2002-02-18
WO2002012336A9 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
AU2959595A (en) Camptothecin drug combinations and medicaments with reduced side effects
EP1491093A3 (en) Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
EP1572961A4 (en) Actriib fusion polypeptides and uses therefor
WO2000056297A3 (en) Pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth
HUS1400034I1 (en) Use of dialkylfumarates for producing pharmaceutical compositions for the treatment autoimmune diseases
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
AU3368497A (en) Human dnase i hyperactive variants
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
WO2001091728A3 (en) Nanoemulsion formulations
FI962154A (en) Composition for the in vivo preparation of therapeutic products
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
WO2003066661A3 (en) Human dr4 antibodies and uses thereof
WO2000073452A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002024883A3 (en) Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions
MY128362A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
WO1997020933A3 (en) Mutational variants of mammalian ob gene proteins
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
EP1080724A4 (en) Mtp activity-lowering compositions
AU5926400A (en) Antimicrobial artificial nail composition and methods for preparing and using same
AU2821200A (en) Matrix protein compositions for grafting
WO2002012336A3 (en) TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
WO2003004517A3 (en) Peyers's patch and/or m-celle targeting ligands
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/24-24/24, DRAWINGS, REPLACED BY NEW PAGES 1/17-17/17; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP